BR102375 is a non-TZDperoxisome proliferator-activated receptorγ (PPARγ) full agonist for the treatment of type 2 diabetes, revealsEC₅₀value of 0.28 μM andA_maxratio of 98%^[1].

BR102375 (Compound 18) (10 μM) increases gene expression levels relevant to PPARγ activation and enhances glucose uptake under insulin stimulation^[1].
BR102375 (Compound 18) (10 nM, 100 nM, 1 μM; 6 days, 14 days) shows a concentration-dependent, insulin-sensitive effects on adipogenesis^[1].

BR102375 (Compound 18) has decent efficacy on mouse diabetes model^[1].
BR102375 reveals significant suppressive effect on random blood glucose increase(75 mpk, p.o., bid), shows decent effect on insulin resistance on Oral glucose tolerance test (OGTT) and discloses similar findings in body weight gain almost identical to Pioglitazone^[1].

554.64

C₃₁H₃₄N₆O₄

2366255-59-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.